Illinois Municipal Retirement Fund Buys New Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Illinois Municipal Retirement Fund purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 78,101 shares of the biopharmaceutical company’s stock, valued at approximately $2,351,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bleakley Financial Group LLC bought a new stake in shares of TG Therapeutics in the fourth quarter worth about $245,000. Castellan Group purchased a new position in TG Therapeutics during the 4th quarter valued at approximately $8,539,000. Oppenheimer & Co. Inc. bought a new stake in TG Therapeutics in the 3rd quarter worth approximately $759,000. Segall Bryant & Hamill LLC purchased a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $1,225,000. Finally, Barclays PLC boosted its position in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after acquiring an additional 158,323 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

Analyst Ratings Changes

TGTX has been the topic of several research reports. JPMorgan Chase & Co. boosted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday, November 25th. StockNews.com cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 31st. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Wednesday, January 15th. Finally, The Goldman Sachs Group lifted their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Stock Down 2.8 %

NASDAQ TGTX opened at $28.53 on Friday. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $36.84. The firm has a market capitalization of $4.44 billion, a price-to-earnings ratio of -285.27 and a beta of 2.26. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a fifty day moving average of $30.79 and a two-hundred day moving average of $27.98.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.